

Preferred Lab Partners

The joint venture clinical laboratory between St. Elizabeth Healthcare and Tri-Health

Laboratory Testing Update

On October 1st, 2025, Syphilis testing will be transitioned from the Abbott Architect immunoassay platform to the Roche Cobas e801 immunoassay platform:

Current Methodology: Chemiluminescence

New Methodology: Electrochemiluminescence

The order number will remain the same and reactive specimens will continue to reflex to an RPR

Results will be reported as reactive or non-reactive

Results will not be reported with the cutoff index as it is currently

If you have any questions please contact Amy Binion, Immunology Manager, at 859 301-2077.

Covington Dearborn Edgewood Florence Ft. Thomas Grant